Agile Therapeutics Inc. [AGRX] stock for 22,500 USD was bought by ALTOMARI ALFRED

The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Agile Therapeutics Inc. shares valued at $22,500 were purchased by ALTOMARI ALFRED on Aug 26. At $0.45 per share, ALTOMARI ALFRED acquired 50,000 shares. The insider’s holdings grew to 64,343 shares worth approximately $19302.899999999998 following the completion of this transaction.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Also, PERCEPTIVE ADVISORS LLC purchased 5,734,560 shares, netting a total of over 4,874,376 in proceeds. Following the buying of shares at $0.85 each, the insider now holds 21,654,485 shares.

As of November 29, 2018, Maxim Group has initiated its “Buy” rating for AGRX. Earlier on December 26, 2017, William Blair downgraded its rating. Their new recommendation was “a Mkt perform” for AGRX stock which previously was a “an Outperform”.

Analyzing AGRX’s Price Performance

On Thursday, Agile Therapeutics Inc. [NASDAQ: AGRX] plunged -11.20% to $0.30. The stock’s lowest price that day was $0.2822, but it reached a high of $0.3449 in the same session. During the last five days, there has been a drop of approximately -24.30%. Over the course of the year, Agile Therapeutics Inc. shares have dropped approximately -98.45%. Shares of the company reached a 52-week high of $21.3400 on 01/03/22 and a 52-week low of $0.2822 on 09/22/22. A 50-day SMA is recorded $0.4873, while a 200-day SMA reached $7.0576. Nevertheless, trading volume fell to 2.37 million shares from 0.69 million shares the previous day.

Support And Resistance Levels for Agile Therapeutics Inc. (AGRX)

According to the 24-hour chart, there is a support level at 0.2750, which, if violated, would cause prices to drop to 0.2473. In the upper region, resistance lies at 0.3377. The next price resistance is at 0.3727. RSI (Relative Strength Index) is 26.05 on the 14-day chart, showing oversold technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.0416, which suggests the price will decrease in the coming days. Percent R is at 85.86%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.

Is Agile Therapeutics Inc. subject to short interest?

Stocks of Agile Therapeutics Inc. saw a sharp rise in short interest on Jul 14, 2022 jumping by 0.29 million shares to 0.77 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 0.48 million shares. A jump of 37.63% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 0.03 of the overall float, the days-to-cover ratio (short ratio) jumped to 0.03.

Which companies own the most shares of Agile Therapeutics Inc. (AGRX)?

According to Perceptive Advisors LLC filings, the company currently owns 532,361 shares, which is about 1.36% of the total AGRX shares outstanding. In its current portfolio, The Vanguard Group, Inc. holds 29,419 shares valued at $11856.0.

In terms of Agile Therapeutics Inc. share price expectations, FactSet research, analysts set an average price target of $3.00 in the next 12 months, up nearly 782.35% from the previous closing price of $0.34. Analysts anticipate Agile Therapeutics Inc. stock to reach $5.00 by 2022, with the lowest price target being $1.00. In spite of this, 2 analysts ranked Agile Therapeutics Inc. stock as a Buy at the end of 2022.

LEAVE A REPLY

Please enter your comment!
Please enter your name here